Search over 3,000 reports

    Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025

    Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025
    Date: Aug, 2017
    Type: Pharmaceutical Industry Report
    Pages: 221
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0009

    Cutaneous T-Cell Lymphoma – Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025” report provides the comprehensive insights on the competitive landscape and market of Cutaneous T-Cell Lymphoma. The Report covers an overview of the disease and market trends of the Cutaneous T-Cell Lymphoma for the seven major markets i.e., the United States, Europe (France, Germany, Italy, Spain, UK) and Japan. 

    The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Cutaneous T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecast of the epidemiology of Cutaneous T-Cell Lymphoma till 2025.The Report also covers market drivers, market barriers, and unmet medical need. The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous T-Cell Lymphoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/ Combination products and Molecule Type drug analysis. 

    It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments, and SWOT Analysis. Cutaneous T-Cell Lymphoma is the rare type of Lymphoma which arises from the skin. It is characterized by the flat red patches on the skin. It can also affect the blood, lymph nodes and internal organs among patients with advanced stage. It is more common among males as compared to females. According to DelveInsight, the Cutaneous T-Cell Lymphoma market size in 7MM is estimated to increase at a compound annual growth rate (CAGR) of 1.6% for the forecasted period i.e., 2013-2025. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts. 

    Scope of the report 

    • Overview of the Global pipeline scenario for Cutaneous T-Cell Lymphoma, products and associated companies information 
    • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities. 
    • The Report provides detailed historical and forecasted epidemiological data of Cutaneous T-Cell Lymphoma in the 7MM i.e., the United States, Europe (Germany, Spain, Italy, France and the United Kingdom) and Japan from 2013-2025. 
    • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-Cell Lymphoma in the US, Europe (Germany, Spain, Italy, France and the United Kingdom) and Japan. 
    • To understand the future market competition in the global Cutaneous T-Cell Lymphoma market and Insightful review of the key market drivers and barriers. 
    • The report will help in developing business strategies by understanding the trends shaping and driving the global Cutaneous T-Cell Lymphoma market. 
    • Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis 
    • The Report also covers the detailed historical and forecasted Cutaneous T-Cell Lymphoma market covering the United States, Europe (Germany, Spain, Italy, France and the United Kingdom) and Japan from 2013-2025. 

    Report Introduction 
    Cutaneous T- Cell Lymphoma Market Overview at a Glance 

    Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2016 
    Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2025 

    Cutaneous T- Cell Lymphoma 

    o Introduction
    o Types 
    o Causes 
    o Pathophysiology 
    o Symptoms 
    o Diagnosis 

    Epidemiology of Cutaneous T-Cell Lymphoma 
    United States 

    o Assumptions and Rationale 
    o Incident Population of Cutaneous T-Cell Lymphoma 
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United States 
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United States 
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States 

    Europe 
    o Assumptions and Rationale 

    Germany 
    o Incident Population of Cutaneous T-Cell Lymphoma in Germany 
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 

    France 

    o Incident Population of Cutaneous T-Cell Lymphoma in France 
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France 
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France 
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France 

    Italy 

    o Incident Population of Cutaneous T-Cell Lymphoma in Italy 
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 

    Spain 

    o Incident Population of Cutaneous T-Cell Lymphoma in Spain 
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 


    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 

    United Kingdom 

    o Incident Population of Cutaneous T-Cell Lymphoma in UK 
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the United Kingdom 
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom 
     Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK 

    Japan 

    o Incident Population of Cutaneous T-Cell Lymphoma in Japan 
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 

    Treatment Algorithm 

    o International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas 
    o United States 
    NCCN Guidelines 

    o Europe 
    ESMO Guidelines 
    Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines 
    EORTC recommendations for the treatment of mycosis fungoides/Se´zary syndrome 

    Unmet Needs 
    Competitive Marketed Drug Landscape 

    o Istodax (Romidepsin): Celgene Corporation 
    Drug Description 
    Mechanism of Action 
    Advantages & Disadvantages 
    Safety and Efficacy 
    Product Profile 

    Marketed Drug List Continued… 
    Competitive Pipeline Landscape 
    o Emerging Therapies 
    Brentuximab Vedotin: Seattle Genetics 
    Product Description 
    Research and Development 
    Product Development Activities 
    Product Profile 

    Emerging Drug List Continued… 

    o Comparative Analysis 
    Clinical Stage Products 
    Pre-Clinical Stage Products 

    o Therapeutic Assessment 

    Assessment by Monotherapy Products 
    Assessment by Combination Products 
    Assessment by Route of Administration 
    Assessment by Stage and Route of Administration 
    Assessment by Molecule Type 
    Assessment by Stage and Molecule Type 
    Assessment by Domain 
    Assessment by Stage and Domain 

    Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis 

    Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2013 2025 
    United States 
    o Market Size of CTCL in United States 
    o Stage-Specific Market Size(Early&Late) of CTCL in United States 

    Europe 
    Germany 

    o Market Size of CTCL in Germany 
    o Stage-Specific Market Size(Early&Late) of CTCL in Germany 

    France 

    o Market Size of CTCL in France 
    o Stage-Specific Market Size(Early&Late) of CTCL in France 

    Italy 

    o Market Size of CTCL in Italy 
    o Stage-Specific Market Size(Early&Late) of CTCL in Italy 

    Spain 

    o Market Size of CTCL in Spain 
    o Stage-Specific Market Size(Early&Late) of CTCL in Spain 

    United Kingdom 

    o Market Size of CTCL in the United Kingdom 
    o Stage-Specific Market Size(Early&Late) of CTCL in United Kingdom 

    Japan 

    o Market Size of CTCL in Japan 
    o Stage-Specific Market Size(Early&Late) of CTCL in Japan 

    Market Drivers 
    Market Restraints 
    Appendix 
    Report Methodology 
    Consulting Services 
    Disclaimer 
    About DelveInsight 

    Table 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)  
    Table 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)  
    Table 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)  
    Table 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)  
    Table 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)  
    Table 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)  
    Table 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)  
    Table 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)  
    Table 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)  
    Table 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)  
    Table 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)  
    Table 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)  
    Table 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)  
    Table 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)  
    Table 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)  
    Table 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)  
    Table 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)  
    Table 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)  
    Table 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)  
    Table 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)  
    Table 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)  
    Table 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)  
    Table 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)  
    Table 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)  
    Table 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)  
    Table 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)  
    Table 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)  
    Table 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)  
    Table 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017  
    Table 30:Clinical Trials by Recruitment status, 2017  
    Table 31: Number of Products under development by Companies, 2017  
    Table 32: Clinical Stage Products, 2017  
    Table 33: Pre-Clinical Stage Products, 2017  
    Table 34: Assessment by Monotherapy Products, 2017  
    Table 35: Assessment by Combination Products, 2017  
    Table 36: Assessment by Route Of Administration, 2017  
    Table 37: Assessment by Stage and Route Of Administration, 2017  
    Table 38: Assessment by Molecule Type, 2017  
    Table 39: Assessment by Stage and Molecule Type, 2017  
    Table 40: Assessment by Stage of development and Domain, 2017  
    Table 41: Recommendations for treatment of CTCL by Radiation Therapy  
    Table 42: Recommendations for treatment of MF stages IA, IB, and IIA 
    Table 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma 
    Table 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025) 
    Table 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Table 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025) 
    Table 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Table 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma inGermany in USD, Million (2013-2025) 
    Table 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Table 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025) 
    Table 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Table 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025) 
    Table 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Table 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025) 
    Table 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Table 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025) 
    Table 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Table 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)

    Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025) 
    Figure 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025) 
    Figure 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025) 
    Figure 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025) 
    Figure 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025) 
    Figure 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025) 
    Figure 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025) 
    Figure 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025) 
    Figure 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025) 
    Figure 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025) 
    Figure 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025) 
    Figure 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025) 
    Figure 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025) 
    Figure 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025) 
    Figure 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025) 
    Figure 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025) 
    Figure 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025) 
    Figure 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025) 
    Figure 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025) 
    Figure 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025) 
    Figure 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025) 
    Figure 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025) 
    Figure 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025) 
    Figure 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025) 
    Figure 25: Incident Population of Cutaneous T-Cell Japan (2013-2025) 
    Figure 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025) 
    Figure 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025) 
    Figure 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025) 
    Figure 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017 
    Figure 30:Clinical Trials by Recruitment status, 2017 
    Figure 31: Number of Products under development by Companies, 2017 
    Figure 32: Clinical Stage Products, 2017 
    Figure 33: Pre-Clinical Stage Products, 2017 
    Figure 34: Assessment by Monotherapy Products, 2017 
    Figure 35: Assessment by Combination Products, 2017 
    Figure 36: Assessment by Route Of Administration, 2017 
    Figure 37: Assessment by Stage and Route Of Administration, 2017 
    Figure 38: Assessment by Molecule Type, 2017 
    Figure 39: Assessment by Stage and Molecule Type, 2017 
    Figure 40: Assessment by Stage of development and Domain, 2017 
    Figure 41: Recommendations for treatment of CTCL by Radiation Therapy 
    Figure 42: Recommendations for treatment of MF stages IA, IB, and IIA 
    Figure 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma 
    Figure 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025) 
    Figure 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Figure 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025) 
    Figure 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Figure 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma inGermany in USD, Million (2013-2025) 
    Figure 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Figure 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025) 
    Figure 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Figure 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025) 
    Figure 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Figure 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025) 
    Figure 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Figure 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025) 
    Figure 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025) 
    Figure 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025) 

     

    Celgene Corporation
    Kyowa Hakko Kirin Co, Ltd.
    Actelion Pharmaceuticals
    Mallinckrodt Pharmaceuticals
    Eisai Co., Ltd.
    Merck Sharp & Dohme Corp.
    Seattle Genetics
    Soligenix
    Janssen
    4SC AG
    Medivir AB
    • Single User License
      $6,950.00
    • Site License
      $13,900.00
    • Global License
      $20,850.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap